ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2511

What Influences Patients’ Opinion of Remission and Low Disease Activity in Psoriatic Arthritis? Principal Component Analysis of an International Study

Laura Coates1, Danielle Robinson 2, Ana-Maria Orbai 3, Uta Kiltz 4, Ying-Ying Leung 5, Penelope Palominos 6, Juan Cañete 7, Rossana Scrivo 8, Andra Balanescu 9, Emmanuelle Dernis 10, Sandra Talli 11, Adeline Ruyssen-Witrand 12, Lihi Eder 13, Maarten de Wit 14, Josef Smolen 15, Ennio Lubrano 16 and Laure Gossec 17, 1University of Oxford, Oxford, United Kingdom, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 3Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 4Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, 5Department of Rheumatology and Immunology, Singapore General Hospital,, Singapore, Singapore, 6Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul,, Porto Alegra, Brazil, 7Rheumatology Department, Hospital Clínic and IDIBAPS,, Barcelona, Spain, 8Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza Università di Roma,, Rome, Italy, 9Sf Maria Hospital, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania, 10Rheumatology Department, Le Mans Central Hospital, Le Mans, France, 11Rheumatology Department, East-Tallinn Central Hospital, Tallinn, Estonia, 12Rheumatology Unit, Toulouse university Hospital, UMR 1027, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France, 13Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, 14Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, 15Medical University of Vienna, Vienna, Austria, 1615. Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ’Vincenzo Tiberio’, University of Molise, Campobasso, Italy, 17Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Patient Satisfaction and Disease Activity, Psoriatic arthritis, remission

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: In psoriatic arthritis (PsA), the objective of treatment is remission or low disease activity (LDA), but there is little research into patients’ perception of remission. The aim of this analysis was to identify which factors associate with patient-defined remission.

Methods: This is an analysis of ReFlap (NCT03119805), a cross-sectional international study of consecutive adult patients with PsA > 2 years of disease duration. Remission was defined by a positive response to the question “At this time, is your psoriatic arthritis in remission, if this means: you feel your disease is as good as gone?”; LDA by the question “At this time, are you in low disease activity, if this means: your disease is in low activity but it’s not as good as gone?”.

Potential variables that may associate with the opinion of remission/LDA were analysed using stepwise multivariable logistic regression. Variables were demographic (age, gender, disease duration, Groll comorbidity index), disease-related (joint counts, psoriasis body surface area (BSA), enthesitis, CRP), patient-reported outcomes (pain, PsAID, HAQ) and physician opinion of cause of symptoms (physician score for symptoms due to PsA, to joint damage or to other disease all scored 0-10). Due to high levels of correlation between variables, principal component analysis (PCA) was used to explore clustered components  associated with remission/LDA. PCA was used to extract factors with orthogonal rotation. Factors with an eigenvalue of ≥1 were included.

Results: Among 466 recruited cases, 31 did not meet inclusion criteria and 11 had missing data leaving 424 for analysis. A total of 94 (22.2%) patients self-classified as remission and 285 (67.2%) as low disease activity or remission. 

When exploring factors associated with patients’ opinion of remission in multivariate analysis, pain, psoriasis BSA, PsAID total score, NRS of physician score of symptoms related to joint damage and Groll comorbidity index were identified as independent predictors. For LDA, results were similar except for the addition of physician global and loss of psoriasis as significant predictors (table 1).

As PCA cannot include binary variables, PCA was performed separately by gender. For remission, variance explained by the key factors was 74% for men and 80% for women. Key factors (table 2) for remission were, for both genders, disease impact (PsAID, pain, HAQ). Other factors identified included MSK disease activity, chronicity/joint damage, psoriasis BSA, enthesitis and CRP. For women, physician’s opinion of symptoms related to other disease was a separate factor. For LDA, similar factors were identified but the percentage variance explained was lower (64-68%).

Conclusion: When considering the patients’ opinion of remission, a number of factors contribute to this perception dominated by disease impact measured by pain, PsAID and HAQ.  In addition, disease activity in all domains, chronicity/age, comorbidities and other conditions contribute to a robust model highlighting how multifaceted “remission” can be for individuals.


table 1

Table 1 –Multivariate analysis of factors associated with patients’ opinion of remission and LDA


table 2

Table 2: Principal component analysis of factors associated with patients’ opinion of remission


Disclosure: L. Coates, Abbvie, 2, 5, 8, AbbVie, 2, 5, 8, AbbVie, Amgen, BMS, Celgene Corporation, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Prothena, Sun Pharma, UCB, 5, Abbvie, Amgen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB, 5, Abbvie, Amgen, Lilly, Novartis, Pfizer, UCB, 8, AbbVie, Celgene Corporation, Eli Lilly, Janssen, Novartis, UCB, 8, AbbVie, Celgene Corporation, Eli Lilly, Novartis, Pfizer, 2, AbbVie, Celgene Corporation, Novartis, Pfizer, 2, Abbvie, Celgene, Novartis, Pfizer, Lilly, 2, Amgen, 5, 8, Biogen, 8, Bristol-Myers Squibb, 5, Celgene, 2, 5, 8, Eli Lilly, 2, 5, 8, Galapagos, 5, Gilead, 5, Janssen, 2, 5, 8, Janssen Research & Development, LLC, Lilly, 2, 5, 8, MSD, 5, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Pfizer Inc, 2, 5, 8, Prothena, 5, Sun Pharma, 5, UCB, 5, 8, UCB Pharma, 5; D. Robinson, None; A. Orbai, AbbVie, 2, Celgene, 2, Eli Lilly, 2, 5, Horizon, 2, Janssen, 2, 5, Lilly, 2, 5, Novartis, 2, 5, Pfizer, 5, UCB, 5; U. Kiltz, AbbVie, 2, 5, 8, ABBVIE, NOVARTIS, CHUGAI, JANSEN, MSD, UCB, 8, ABBVIE, NOVARTIS, LILLY,BIOCAD, GRUNENTHAL,UCB, 5, ABBVIE, NOVARTIS, PFIZER,BIOGEN, 2, Biocad, 2, 5, Biogen, 2, 5, Chugai, 2, 5, 8, Eli Lilly, 2, 5, Eli Lilly and Company, 5, Grünenthal, 2, 5, 8, Janssen, 8, Jasnssen, 2, 5, MSD, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, Roche, 2, 5, 8, UCB, 2, 5, 8; Y. Leung, None; P. Palominos, None; J. Cañete, None; R. Scrivo, None; A. Balanescu, None; E. Dernis, None; S. Talli, None; A. Ruyssen-Witrand, None; L. Eder, Abbvie, 2, 5, 8, Celgene, 5, Janssen, 5, Lily, 2, 5, Novartis, 2, 5, Pfizer, 2, 8, UCB, 2; M. de Wit, Abbvie, 5, 8, BMS, 5, 8, Celgene, 5, 8, Eli Lilly, 5, 8, Janssen-Cilag, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Roche, 5, 8; J. Smolen, AbbVie, 2, 5, 8, Abbvie, 2, 5, Amgen, 5, 8, AstraZeneca, 2, 5, 8, Astra-Zeneca, 5, Astro, 5, 8, BMS, 5, Celgene, 5, 8, Celltrion, 5, Celtrion, 5, 8, Chugai, 5, Eli Lilly and Company, 2, 5, Gilead, 5, GlaxoSmithKline, 5, 8, ILTOO, 5, 8, ILTOO Janssen, 5, Janssen, 2, 5, 8, Lilly, 2, 5, 8, Medimmune, 5, 8, MSD, 2, 5, 8, Novartis, 2, 5, Novartis- Sandoz, 5, Novartis-Sandoz, 2, 5, 8, Pfizer, 2, 5, 8, Pfizer Inc, 5, Roche, 2, 5, Roche;, 2, 5, 8, Samsung, 5, 8, Sanofi, 5, 8, Sanofi-Aventis, 5, UCB, 5, 8; E. Lubrano, None; L. Gossec, None.

To cite this abstract in AMA style:

Coates L, Robinson D, Orbai A, Kiltz U, Leung Y, Palominos P, Cañete J, Scrivo R, Balanescu A, Dernis E, Talli S, Ruyssen-Witrand A, Eder L, de Wit M, Smolen J, Lubrano E, Gossec L. What Influences Patients’ Opinion of Remission and Low Disease Activity in Psoriatic Arthritis? Principal Component Analysis of an International Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/what-influences-patients-opinion-of-remission-and-low-disease-activity-in-psoriatic-arthritis-principal-component-analysis-of-an-international-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/what-influences-patients-opinion-of-remission-and-low-disease-activity-in-psoriatic-arthritis-principal-component-analysis-of-an-international-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology